AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36464571 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS) for 20 min
Number of subjects: 105
Study 36464571 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 105
Study 34148351 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban or rivaroxaban (direct acting oral anticoagulation)
Number of subjects: 1421
Study 32957929 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil plasma target concentration 0.0 ng ml-1 (Group S0)
Number of subjects: 85
Study 32957929 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil plasma target concentration 0.1 ng ml-1 (Group S1)
Number of subjects: 85
Study 32957929 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil plasma target concentration 0.3 ng ml-1 (Group S2)
Number of subjects: 85
Study 32957929 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil plasma target concentration 0.5 ng ml-1 (Group S3)
Number of subjects: 85
Study 32957929 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil plasma target concentration 0.7 ng ml-1 (Group S4)
Number of subjects: 85
Study 36159012 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics signature, alpha-fetoprotein (AFP), neutrophil-to-lymphocyte ratio (NLR)
Number of subjects: 150
Study 32229523 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated partner therapy (APT)
Number of subjects: 5440
Study 32229523 — intervention group
Group type: COMPARATOR
Intervention: Standard partner notification (PN)
Number of subjects: 5440
Study 33371995 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse Administered Propofol Sedation (NAPS)
Number of subjects: 130
Study 33371995 — intervention group
Group type: COMPARATOR
Intervention: Moderate midazolam and fentanyl sedation
Number of subjects: 130
Study 35994347 — intervention group
Group type: EXPERIMENTAL
Intervention: Active washing filtration system (Revolve system)
Number of subjects: 46
Study 35994347 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive washing filtration system (Puregraft system)
Number of subjects: 46
Study 35994347 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrifugation (Coleman technique)
Number of subjects: 46
Study 35994347 — intervention group
Group type: COMPARATOR
Intervention: All groups (comparison)
Number of subjects: 46
Study 33190147 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 carboxylic acid (4 g/d)
Number of subjects: 13078
Study 33190147 — intervention group
Group type: COMPARATOR
Intervention: Corn oil (inert comparator)
Number of subjects: 13078
Study 35597286 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-guided self-prone positioning
Number of subjects: 293
Study 34535694 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic risk score (GRS) 50
Number of subjects: 12120
Study 34535694 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic risk score (GRS) 27
Number of subjects: 12120
Study 34535694 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithms including paternal information and GRS
Number of subjects: 12120
Study 34535694 — intervention group
Group type: COMPARATOR
Intervention: Algorithms including GRS only
Number of subjects: 12120
Study 33603939 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL of 0.375% ropivacaine with 100 ng of naloxone
Number of subjects: 74
Study 33603939 — intervention group
Group type: COMPARATOR
Intervention: 20 mL of 0.375% ropivacaine
Number of subjects: 74
Study 33187170 — intervention group
Group type: EXPERIMENTAL
Intervention: Unhealthy lifestyle (poor diet, lower intensity of physical exercise, higher alcohol intake, smoking)
Number of subjects: 335
Study 33187170 — intervention group
Group type: EXPERIMENTAL
Intervention: Sociodemographic factors (being older, in a relationship, and employed)
Number of subjects: 335
Study 33187170 — intervention group
Group type: EXPERIMENTAL
Intervention: Risky sexual behaviors (lower use of condoms, higher frequency of risky sexual behaviors)
Number of subjects: 335
Study 34652445 — intervention group
Group type: EXPERIMENTAL
Intervention: β-lactam (amoxicillin-clavulanate [1 g/125 mg] 3 times daily) for 5 extra days
Number of subjects: 291
Study 34652445 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 5 extra days
Number of subjects: 291
Study 34252001 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 repetitions of 20m sprint accelerations (S)
Number of subjects: 0
Study 34252001 — intervention group
Group type: EXPERIMENTAL
Intervention: 3x10 alternative leg weighted bounding (P)
Number of subjects: 0
Study 34252001 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 0
Study 32305106 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g TXA
Number of subjects: 100
Study 32305106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 35361168 — intervention group
Group type: EXPERIMENTAL
Intervention: MULTI +
Number of subjects: 0
Study 35361168 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 0
Study 33685237 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed high-intensity laser therapy (HILT)
Number of subjects: 51
Study 33685237 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field (EMF)
Number of subjects: 51
Study 32799792 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine 0.5 mg/kg intravenously
Number of subjects: 90
Study 32799792 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 90
Study 32799792 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (KT and control)
Number of subjects: 90
Study 34656072 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Number of subjects: 22
Study 34656072 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole with cola
Number of subjects: 22
Study 33876306 — intervention group
Group type: EXPERIMENTAL
Intervention: High tie (HT) vascular ligation
Number of subjects: 208
Study 33876306 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tie (LT) vascular ligation
Number of subjects: 208
Study 33876306 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tie plus lymph node dissection (LT-appic LND)
Number of subjects: 208
Study 33707982 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching (30s × 1 set)
Number of subjects: 36
Study 33707982 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching (30s × 3 repetitions)
Number of subjects: 36
Study 33707982 — intervention group
Group type: EXPERIMENTAL
Intervention: Long duration stretching (30s × 10 sets)
Number of subjects: 36
Study 33707982 — intervention group
Group type: COMPARATOR
Intervention: Short duration stretching (30s × 1 set)
Number of subjects: 36
Study 33512943 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 sessions of radial extracorporeal shockwave therapy (rESWT) at the 'recommended'/'maximally comfortably tolerated' dose
Number of subjects: 120
Study 33512943 — intervention group
Group type: COMPARATOR
Intervention: 3 sessions of radial extracorporeal shockwave therapy (rESWT) at 'minimal dose'
Number of subjects: 120
Study 33512943 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (recommended dose and minimal dose)
Number of subjects: 120
Study 33512943 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 sessions of rESWT (both doses)
Number of subjects: 120
Study 34158017 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapeutic consultation at work (up to 17 sessions of psychotherapy, including work-related diagnostics and consultations)
Number of subjects: 520
Study 34158017 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 520
Study 34158017 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-benefit assessment related to costs of common mental disorders for social insurances and companies
Number of subjects: 520
Study 35510753 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense pulsed light (IPL) combined with minocycline (100 mg per day for 8 weeks)
Number of subjects: 40
Study 35510753 — intervention group
Group type: COMPARATOR
Intervention: Minocycline only (100 mg per day for 8 weeks)
Number of subjects: 40
Study 32146687 — intervention group
Group type: EXPERIMENTAL
Intervention: Barbed sutures
Number of subjects: 60
Study 32146687 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care sutures
Number of subjects: 60
Study 36072252 — intervention group
Group type: EXPERIMENTAL
Intervention: Scrambler Therapy (ST)
Number of subjects: 80
Study 36072252 — intervention group
Group type: COMPARATOR
Intervention: Control (pain management drugs following the WHO analgesic ladder)
Number of subjects: 80
Study 33947448 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated audit and feedback intervention delivered electronically 4 times over 12 months.
Number of subjects: 0
Study 33120777 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) combined with antidepressants
Number of subjects: 60
Study 33120777 — intervention group
Group type: COMPARATOR
Intervention: Antidepressants only (Control)
Number of subjects: 60
Study 35578544 — intervention group
Group type: EXPERIMENTAL
Intervention: Store-and-forward teledermatology system
Number of subjects: 388
Study 35578544 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 388
Study 33694206 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored-Ablation Index (TAI) protocol
Number of subjects: 100
Study 33694206 — intervention group
Group type: COMPARATOR
Intervention: Force-Time Integral (FTI) protocol
Number of subjects: 100
Study 32645161 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin as a cardiovascular disease prevention strategy
Number of subjects: 7770
Study 33721562 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg intravenously every 3 weeks
Number of subjects: 304
Study 33721562 — intervention group
Group type: COMPARATOR
Intervention: Brentuximab vedotin 1.8 mg/kg intravenously every 3 weeks
Number of subjects: 304
Study 33721562 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 304
Study 33721562 — intervention group
Group type: COMPARATOR
Intervention: Brentuximab vedotin
Number of subjects: 304
Study 34261908 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course antibiotic therapy (7 days or less) after removal of the central venous catheter (CVC)
Number of subjects: 0
Study 34261908 — intervention group
Group type: COMPARATOR
Intervention: Long-course antibiotic therapy (7-14 days)
Number of subjects: 0
Study 32269083 — intervention group
Group type: EXPERIMENTAL
Intervention: Loneliness (measured using a 6-item Loneliness Scale for Emotional and Social Loneliness)
Number of subjects: 770
Study 32269083 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-rated physical health (assessed as poor, fair, good, very good, or excellent)
Number of subjects: 770
Study 32269083 — intervention group
Group type: COMPARATOR
Intervention: Self-rated physical health (poor/fair)
Number of subjects: 770
Study 32269083 — intervention group
Group type: EXPERIMENTAL
Intervention: Loneliness
Number of subjects: 770
Study 32269083 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptomatology
Number of subjects: 770
Study 36369798 — intervention group
Group type: EXPERIMENTAL
Intervention: Deucravacitinib 3 mg twice daily
Number of subjects: 363
Study 36369798 — intervention group
Group type: EXPERIMENTAL
Intervention: Deucravacitinib 6 mg twice daily
Number of subjects: 363
Study 36369798 — intervention group
Group type: EXPERIMENTAL
Intervention: Deucravacitinib 12 mg once daily
Number of subjects: 363
Study 36369798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 363
Study 36369798 — intervention group
Group type: EXPERIMENTAL
Intervention: Deucravacitinib (all doses)
Number of subjects: 363
Study 35714812 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK3389404 (60 mg weekly)
Number of subjects: 66
Study 35714812 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK3389404 (120 mg weekly)
Number of subjects: 66
Study 35714812 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK3389404 (120 mg bi-weekly)
Number of subjects: 66
Study 35714812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 35714812 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK3389404
Number of subjects: 66
Study 35714812 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK3389404 (120 mg weekly, 120 mg bi-weekly)
Number of subjects: 66
Study 33380248 — intervention group
Group type: EXPERIMENTAL
Intervention: IV Methylprednisolone
Number of subjects: 61
Study 33380248 — intervention group
Group type: EXPERIMENTAL
Intervention: IV Hydrocortisone
Number of subjects: 61
Study 33380248 — intervention group
Group type: EXPERIMENTAL
Intervention: IV Dexamethasone
Number of subjects: 61
Study 34553379 — intervention group
Group type: EXPERIMENTAL
Intervention: Re:MIX program cofacilitated by professional health educators and young parent educators
Number of subjects: 57
Study 34553379 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 57
Study 32932891 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided injection of Botulinum Toxin Type A (24 U)
Number of subjects: 20
Study 32932891 — intervention group
Group type: COMPARATOR
Intervention: Conventional blind injection of Botulinum Toxin Type A (24 U)
Number of subjects: 20
Study 34209804 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacticaseibacillus paracasei strain Shirota (LcS) beverage (100 mL, 108 CFU/mL)
Number of subjects: 82
Study 34209804 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 82
Study 34209804 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacticaseibacillus paracasei strain Shirota (LcS) beverage
Number of subjects: 82
Study 35952529 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone IV combined with 15 sessions of hyperbaric oxygen therapy (SS + HBOT)
Number of subjects: 50
Study 35952529 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone IV (SS)
Number of subjects: 50
Study 34355814 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF-1/Risedronate
Number of subjects: 90
Study 34355814 — intervention group
Group type: COMPARATOR
Intervention: Risedronate
Number of subjects: 90
Study 34355814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 32601949 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-based radiomics model
Number of subjects: 145
Study 36513488 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-min dough kneading time (K15)
Number of subjects: 10
Study 36513488 — intervention group
Group type: COMPARATOR
Intervention: 10-min dough kneading time (K10)
Number of subjects: 10
Study 36513488 — intervention group
Group type: EXPERIMENTAL
Intervention: Coarse flour (CF)
Number of subjects: 10
Study 36513488 — intervention group
Group type: COMPARATOR
Intervention: Fine flour (FF)
Number of subjects: 10
Study 33893799 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination + oral polio vaccine (OPV) immediately upon admission
Number of subjects: 3353
Study 33893799 — intervention group
Group type: COMPARATOR
Intervention: BCG vaccination + OPV at hospital discharge (control)
Number of subjects: 3353
Study 33893799 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination + OPV immediately upon admission
Number of subjects: 3353
Study 34973048 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE) therapy
Number of subjects: 98
Study 34973048 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied Relaxation (AR)
Number of subjects: 98
Study 34973048 — intervention group
Group type: COMPARATOR
Intervention: Both treatments (PE and AR)
Number of subjects: 98
Study 36316847 — intervention group
Group type: EXPERIMENTAL
Intervention: NRT + AA
Number of subjects: 40
Study 36316847 — intervention group
Group type: COMPARATOR
Intervention: NRT
Number of subjects: 40
Study 32339320 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsurgical subinguinal varicocelectomy with testicular delivery (TD)
Number of subjects: 181
Study 32339320 — intervention group
Group type: COMPARATOR
Intervention: Microsurgical subinguinal varicocelectomy without testicular delivery (TD)
Number of subjects: 181
Study 35553185 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/day
Number of subjects: 39
Study 35553185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 32093772 — intervention group
Group type: EXPERIMENTAL
Intervention: A-FFIP
Number of subjects: 134
Study 32093772 — intervention group
Group type: COMPARATOR
Intervention: EIAU
Number of subjects: 134
Study 34632490 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide 80 mg bolus
Number of subjects: 276
Study 34632490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276
Study 35866691 — intervention group
Group type: EXPERIMENTAL
Intervention: Propes and Inflamafertin
Number of subjects: 212
Study 35866691 — intervention group
Group type: COMPARATOR
Intervention: Control (no immunotherapy)
Number of subjects: 212
Study 32645158 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy
Number of subjects: 82
Study 35347848 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight control strategies total score
Number of subjects: 0
Study 35347848 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological coping subscale
Number of subjects: 0
Study 35347848 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower baseline BMI
Number of subjects: 0
Study 34211015 — intervention group
Group type: EXPERIMENTAL
Intervention: ΔQRS ≥ 8 ms (group 3)
Number of subjects: 798
Study 34211015 — intervention group
Group type: COMPARATOR
Intervention: ΔQRS < 4 ms (group 1)
Number of subjects: 798
Study 35157001 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tenecteplase
Number of subjects: 0
Study 33393452 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight condition
Number of subjects: 130
Study 33393452 — intervention group
Group type: COMPARATOR
Intervention: Underweight condition
Number of subjects: 130
Study 33745505 — intervention group
Group type: EXPERIMENTAL
Intervention: TSD therapy
Number of subjects: 39
Study 33745505 — intervention group
Group type: COMPARATOR
Intervention: MAD therapy
Number of subjects: 39
Study 32092608 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbreaks every 10 minutes for 10 seconds
Number of subjects: 12
Study 32092608 — intervention group
Group type: COMPARATOR
Intervention: Normal procedures (without microbreaks)
Number of subjects: 12
Study 35850745 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck specific or general exercise intervention
Number of subjects: 172
Study 32175662 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil (2 mg injected into the coronary artery)
Number of subjects: 60
Study 32175662 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (equal volume injected into the coronary artery)
Number of subjects: 60
Study 32175662 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil
Number of subjects: 60
Study 36195924 — intervention group
Group type: EXPERIMENTAL
Intervention: Follitropin delta
Number of subjects: 759
Study 36195924 — intervention group
Group type: COMPARATOR
Intervention: Follitropin alfa
Number of subjects: 759
Study 33952670 — intervention group
Group type: EXPERIMENTAL
Intervention: ticagrelor (180 mg loading dose on day 1 followed by 90 mg twice daily on days 2‐90) plus open-label aspirin (75-300 mg on day 1 followed by 75 mg daily on days 2-21)
Number of subjects: 0
Study 33952670 — intervention group
Group type: COMPARATOR
Intervention: clopidogrel (300 mg loading dose on day 1 followed by 75 mg daily on days 2‐90) plus open-label aspirin (75-300 mg on day 1 followed by 75 mg daily on days 2-21)
Number of subjects: 0
Study 35198025 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal vitamin D3 level group (ND3G)
Number of subjects: 33
Study 35198025 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 33
Study 32361875 — intervention group
Group type: EXPERIMENTAL
Intervention: SD2 (suprapubic tube with micturition on POD 2)
Number of subjects: 198
Study 32361875 — intervention group
Group type: COMPARATOR
Intervention: TD5 (transurethral catheter with micturition on POD 5)
Number of subjects: 198
Study 32361875 — intervention group
Group type: COMPARATOR
Intervention: SD5 (suprapubic tube with micturition on POD 5)
Number of subjects: 198
Study 33080730 — intervention group
Group type: COMPARATOR
Intervention: DACPR with metronome sounds (mDACPR)
Number of subjects: 69
Study 33080730 — intervention group
Group type: EXPERIMENTAL
Intervention: DACPR with metronome sounds and human encouragement (mheDACPR)
Number of subjects: 69
Study 35572164 — intervention group
Group type: EXPERIMENTAL
Intervention: RFE under NMES
Number of subjects: 99
Study 35572164 — intervention group
Group type: COMPARATOR
Intervention: Conventional Training (CT)
Number of subjects: 99
Study 33227454 — intervention group
Group type: EXPERIMENTAL
Intervention: Predeposit autotransfusion (PAT) after surgery
Number of subjects: 0
Study 33227454 — intervention group
Group type: COMPARATOR
Intervention: Control group (no blood transfusion after surgery)
Number of subjects: 0
Study 36224244 — intervention group
Group type: EXPERIMENTAL
Intervention: Active M1‐rTMS (10 Hz for 10 daily treatments over 2 weeks)
Number of subjects: 27
Study 36224244 — intervention group
Group type: COMPARATOR
Intervention: Sham M1‐rTMS
Number of subjects: 27
Study 36224244 — intervention group
Group type: EXPERIMENTAL
Intervention: Active M1‐rTMS
Number of subjects: 27
Study 34352094 — intervention group
Group type: EXPERIMENTAL
Intervention: Undifferentiated arthritis (UA)
Number of subjects: 637
Study 34352094 — intervention group
Group type: EXPERIMENTAL
Intervention: Autoantibody-negative rheumatoid arthritis (RA-)
Number of subjects: 637
Study 34352094 — intervention group
Group type: EXPERIMENTAL
Intervention: Autoantibody-positive rheumatoid arthritis (RA+)
Number of subjects: 637
Study 34352094 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall patient population
Number of subjects: 637
Study 33147621 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopaminergic medication (200/50 mg levodopa-benserazide)
Number of subjects: 63
Study 33147621 — intervention group
Group type: COMPARATOR
Intervention: Control group (OFF medication)
Number of subjects: 63
Study 36461704 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mm short implants
Number of subjects: 30
Study 36461704 — intervention group
Group type: COMPARATOR
Intervention: 11 mm long implants
Number of subjects: 30
Study 36461704 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 30